[{"id":"488850a4-401a-418b-88e8-32f7b6c5f0dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT06038578","created_at":"2023-09-15T18:09:55.230Z","updated_at":"2025-02-25T13:41:43.311Z","phase":"Phase 2","brief_title":"A Study of TRK-950 When Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer","source_id_and_acronym":"NCT06038578","lead_sponsor":"Toray Industries, Inc","biomarkers":" CAPRIN1","pipe":"","alterations":" ","tags":["CAPRIN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Cyramza (ramucirumab) • TRK-950"],"overall_status":"Recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 10/04/2023","start_date":" 10/04/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-21"},{"id":"fc32aaa3-7f5b-404e-9923-86b9a8cde5d8","acronym":"LUNG-MAP SUB-STUDY","url":"https://clinicaltrials.gov/study/NCT06031688","created_at":"2023-09-11T16:10:36.199Z","updated_at":"2025-02-25T14:10:03.191Z","phase":"Phase 2","brief_title":"Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT06031688 - LUNG-MAP SUB-STUDY","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cyramza (ramucirumab) • Tepmetko (tepotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 08/08/2024","start_date":" 08/08/2024","primary_txt":" Primary completion: 05/31/2028","primary_completion_date":" 05/31/2028","study_txt":" Completion: 05/31/2029","study_completion_date":" 05/31/2029","last_update_posted":"2025-02-17"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"868ab017-feca-462a-908a-0cf81a5b86b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04310007","created_at":"2021-01-18T20:53:46.863Z","updated_at":"2025-02-25T16:37:47.177Z","phase":"Phase 2","brief_title":"Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04310007","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • KRAS • BRAF • ALK • ROS1","pipe":" | ","alterations":" KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative","tags":["EGFR • PD-L1 • KRAS • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • lexatumumab (ETR2-ST01) • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 117","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-06"},{"id":"d2d9e6c2-1ef0-4919-8d41-0d38872e5bdf","acronym":"Rambro2","url":"https://clinicaltrials.gov/study/NCT05980000","created_at":"2023-08-07T14:09:08.525Z","updated_at":"2025-02-25T17:26:19.610Z","phase":"Phase 2","brief_title":"Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma","source_id_and_acronym":"NCT05980000 - Rambro2","lead_sponsor":"Washington University School of Medicine","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Cyramza (ramucirumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 10/27/2023","start_date":" 10/27/2023","primary_txt":" Primary completion: 04/30/2028","primary_completion_date":" 04/30/2028","study_txt":" Completion: 04/30/2031","study_completion_date":" 04/30/2031","last_update_posted":"2025-01-31"},{"id":"990e56a9-fdb3-4de5-b212-83f4d38144b8","acronym":"DESTINY-Gastric04","url":"https://clinicaltrials.gov/study/NCT04704934","created_at":"2021-01-19T20:51:20.427Z","updated_at":"2025-02-25T14:59:37.131Z","phase":"Phase 3","brief_title":"Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)","source_id_and_acronym":"NCT04704934 - DESTINY-Gastric04","lead_sponsor":"Daiichi Sankyo","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • Cyramza (ramucirumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 490","initiation":"Initiation: 05/21/2021","start_date":" 05/21/2021","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-10-24"},{"id":"fce3d556-d1c0-4ebd-973c-c01efbeeac27","acronym":"PLATFORM","url":"https://clinicaltrials.gov/study/NCT02678182","created_at":"2021-01-17T17:56:06.364Z","updated_at":"2025-02-25T14:57:30.468Z","phase":"Phase 2","brief_title":"Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial","source_id_and_acronym":"NCT02678182 - PLATFORM","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Imfinzi (durvalumab) • capecitabine • Rubraca (rucaparib) • Cyramza (ramucirumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 494","initiation":"Initiation: 02/01/2015","start_date":" 02/01/2015","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-09-19"},{"id":"784231b9-195e-4cdb-8b0c-3f60c54cd03b","acronym":"KEYNOTE-098","url":"https://clinicaltrials.gov/study/NCT02443324","created_at":"2021-01-17T17:34:42.987Z","updated_at":"2025-02-25T16:14:44.151Z","phase":"Phase 1","brief_title":"A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer","source_id_and_acronym":"NCT02443324 - KEYNOTE-098","lead_sponsor":"Eli Lilly and Company","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Cyramza (ramucirumab)"],"overall_status":"Completed","enrollment":" Enrollment 175","initiation":"Initiation: 07/29/2015","start_date":" 07/29/2015","primary_txt":" Primary completion: 08/31/2018","primary_completion_date":" 08/31/2018","study_txt":" Completion: 04/12/2022","study_completion_date":" 04/12/2022","last_update_posted":"2024-07-31"},{"id":"807435ea-861d-4d9d-b38f-cc3478e08f0f","acronym":"SEQUEL","url":"https://clinicaltrials.gov/study/NCT04069273","created_at":"2021-01-18T19:56:49.913Z","updated_at":"2025-02-25T16:09:26.660Z","phase":"Phase 2","brief_title":"Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma","source_id_and_acronym":"NCT04069273 - SEQUEL","lead_sponsor":"Harry H Yoon","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • paclitaxel • Cyramza (ramucirumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 06/11/2025","primary_completion_date":" 06/11/2025","study_txt":" Completion: 12/10/2025","study_completion_date":" 12/10/2025","last_update_posted":"2024-07-02"},{"id":"23fc48e8-8769-4759-8eb9-b726dad67c99","acronym":"Lung-MAP Non-Matched Sub-Study","url":"https://clinicaltrials.gov/study/NCT03971474","created_at":"2021-01-18T19:32:15.856Z","updated_at":"2024-07-02T16:34:25.767Z","phase":"Phase 2","brief_title":"Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)","source_id_and_acronym":"NCT03971474 - Lung-MAP Non-Matched Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK fusion • ROS1 fusion","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • gemcitabine • docetaxel • Cyramza (ramucirumab) • pemetrexed • lexatumumab (ETR2-ST01)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 166","initiation":"Initiation: 05/28/2019","start_date":" 05/28/2019","primary_txt":" Primary completion: 04/14/2022","primary_completion_date":" 04/14/2022","study_txt":" Completion: 07/15/2024","study_completion_date":" 07/15/2024","last_update_posted":"2024-06-14"},{"id":"a3319e4d-f4d4-4df9-a108-3d23004da6fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT06043427","created_at":"2023-09-21T15:10:26.808Z","updated_at":"2024-07-02T16:34:26.909Z","phase":"Phase 2","brief_title":"Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma","source_id_and_acronym":"NCT06043427","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Cyramza (ramucirumab) • Ziihera (zanidatamab-hrii)"],"overall_status":"Recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 04/16/2024","start_date":" 04/16/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-06-12"},{"id":"4a5cc8d4-4988-48bd-a23f-3af70e820203","acronym":"Lung-MAP Sub-Study","url":"https://clinicaltrials.gov/study/NCT05642572","created_at":"2022-12-08T14:57:35.488Z","updated_at":"2024-07-02T16:34:27.426Z","phase":"Phase 2","brief_title":"Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT05642572 - Lung-MAP Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • MET amplification","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Cyramza (ramucirumab) • Tabrecta (capmatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 05/05/2023","start_date":" 05/05/2023","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2027","study_completion_date":" 05/31/2027","last_update_posted":"2024-06-11"},{"id":"f5bdf194-d00c-403d-a21d-9ca26dbc205a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03527108","created_at":"2021-01-18T17:22:18.280Z","updated_at":"2025-02-25T14:26:57.061Z","phase":"Phase 2","brief_title":"Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC","source_id_and_acronym":"NCT03527108","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" EGFR • PD-L1 • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Cyramza (ramucirumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 10/08/2020","start_date":" 10/08/2020","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-06-06"},{"id":"9de9a1df-22ec-481b-a91e-eefe5c853bd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02791334","created_at":"2021-01-18T13:42:09.109Z","updated_at":"2024-07-02T16:34:59.807Z","phase":"Phase 1","brief_title":"A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors","source_id_and_acronym":"NCT02791334","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2 • ER • PGR • MSI","pipe":" | ","alterations":" MSI-H/dMMR • HER-2 overexpression • HER-2 negative","tags":["HER-2 • ER • PGR • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • HER-2 overexpression • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • Cyramza (ramucirumab) • merestinib (LY2801653) • lodapolimab (LY3300054) • LY3321367"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 215","initiation":"Initiation: 06/29/2016","start_date":" 06/29/2016","primary_txt":" Primary completion: 05/22/2020","primary_completion_date":" 05/22/2020","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-05-31"},{"id":"80ae9b9a-9383-4fbe-a030-18f6cfe6115b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03798626","created_at":"2021-01-18T18:47:09.510Z","updated_at":"2024-07-02T16:35:03.688Z","phase":"Phase 1","brief_title":"Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers","source_id_and_acronym":"NCT03798626","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • paclitaxel • 5-fluorouracil • Cabometyx (cabozantinib tablet) • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • gevokizumab (VPM087)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 167","initiation":"Initiation: 05/22/2019","start_date":" 05/22/2019","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-05-14"},{"id":"7bef29a7-07ed-4332-9706-9ee664c0f131","acronym":"Lung-MAP Non-Match Sub-Study","url":"https://clinicaltrials.gov/study/NCT05096663","created_at":"2021-10-27T14:53:21.327Z","updated_at":"2024-07-02T16:35:05.962Z","phase":"Phase 2/3","brief_title":"Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT05096663 - Lung-MAP Non-Match Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • BRAF • ALK • ROS1 • NTRK","pipe":" | ","alterations":" BRAF mutation • ALK fusion • ROS1 fusion • MET mutation • NTRK fusion","tags":["EGFR • BRAF • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • ALK fusion • ROS1 fusion • MET mutation • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • gemcitabine • docetaxel • Cyramza (ramucirumab) • pemetrexed • Anktiva (nogapendekin alfa inbakicept-pmln) • Hemady (dexamethasone tablets) • Pemfexy (pemetrexed)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 03/15/2022","start_date":" 03/15/2022","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-05-03"},{"id":"382b7b1e-7eba-439f-b058-87ca67c09ec9","acronym":"RamAtezo-1","url":"https://clinicaltrials.gov/study/NCT03689855","created_at":"2021-01-18T18:05:11.654Z","updated_at":"2024-07-02T16:35:06.356Z","phase":"Phase 2","brief_title":"Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC","source_id_and_acronym":"NCT03689855 - RamAtezo-1","lead_sponsor":"Washington University School of Medicine","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" EGFR mutation • ALK mutation","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Cyramza (ramucirumab)"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 06/05/2019","start_date":" 06/05/2019","primary_txt":" Primary completion: 07/16/2021","primary_completion_date":" 07/16/2021","study_txt":" Completion: 04/22/2024","study_completion_date":" 04/22/2024","last_update_posted":"2024-05-02"},{"id":"5339312c-848e-4c0d-aed2-e48d851689d4","acronym":"MORPHEUS-EC","url":"https://clinicaltrials.gov/study/NCT03281369","created_at":"2021-01-18T16:12:10.112Z","updated_at":"2024-07-02T16:35:06.566Z","phase":"Phase 1/2","brief_title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)","source_id_and_acronym":"NCT03281369 - MORPHEUS-EC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • PD-L1 • TIGIT","pipe":" | ","alterations":" HER-2 negative • HER-2 expression","tags":["HER-2 • PD-L1 • TIGIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • paclitaxel • 5-fluorouracil • Cotellic (cobimetinib) • Cyramza (ramucirumab) • oxaliplatin • leucovorin calcium • tiragolumab (RG6058) • pegvorhyaluronidase alfa (PEGPH20) • Aphexda (motixafortide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 410","initiation":"Initiation: 10/13/2017","start_date":" 10/13/2017","primary_txt":" Primary completion: 08/24/2024","primary_completion_date":" 08/24/2024","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-05-01"},{"id":"63f076a8-74c5-4394-bd30-306e1c08b667","acronym":"CARMEN-LC04","url":"https://clinicaltrials.gov/study/NCT04394624","created_at":"2021-01-18T21:12:33.631Z","updated_at":"2024-07-02T16:35:06.670Z","phase":"Phase 2","brief_title":"Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)","source_id_and_acronym":"NCT04394624 - CARMEN-LC04","lead_sponsor":"Sanofi","biomarkers":" CEACAM5","pipe":"","alterations":" ","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Cyramza (ramucirumab) • tusamitamab ravtansine (SAR408701)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 08/31/2020","start_date":" 08/31/2020","primary_txt":" Primary completion: 03/06/2023","primary_completion_date":" 03/06/2023","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-05-01"},{"id":"2496a405-f709-49ff-9442-cc8f42dfeb39","acronym":"RAMOSE","url":"https://clinicaltrials.gov/study/NCT03909334","created_at":"2021-01-18T19:14:34.350Z","updated_at":"2024-07-02T16:35:07.044Z","phase":"Phase 2","brief_title":"Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT03909334 - RAMOSE","lead_sponsor":"Xiuning Le","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Cyramza (ramucirumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 07/25/2019","start_date":" 07/25/2019","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-04-30"},{"id":"587353e8-69d4-43ef-a2e4-48bd6a9a08e3","acronym":"NuTide:302","url":"https://clinicaltrials.gov/study/NCT03428958","created_at":"2021-01-19T15:31:48.117Z","updated_at":"2024-07-02T16:35:11.599Z","phase":"Phase 1/2","brief_title":"A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment","source_id_and_acronym":"NCT03428958 - NuTide:302","lead_sponsor":"NuCana plc","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • KRAS wild-type • RAS wild-type","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • Vectibix (panitumumab) • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • fosifloxuridine nafalbenamide (NUC-3373) • levoleucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 10/16/2018","start_date":" 10/16/2018","primary_txt":" Primary completion: 03/19/2024","primary_completion_date":" 03/19/2024","study_txt":" Completion: 03/21/2024","study_completion_date":" 03/21/2024","last_update_posted":"2024-04-03"},{"id":"99425b86-d7f5-4e13-abcd-98632d9960ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT04660760","created_at":"2021-01-19T20:42:30.744Z","updated_at":"2024-07-02T16:35:12.122Z","phase":"Phase 2","brief_title":"Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer","source_id_and_acronym":"NCT04660760","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • Cyramza (ramucirumab) • Lonsurf (trifluridine/tipiracil) • lexatumumab (ETR2-ST01)"],"overall_status":"Recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 06/16/2021","start_date":" 06/16/2021","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-04-01"},{"id":"53d80059-10cf-4b1e-809f-d51433276602","acronym":"RELAY","url":"https://clinicaltrials.gov/study/NCT02411448","created_at":"2021-01-17T17:40:04.195Z","updated_at":"2024-07-02T16:35:14.291Z","phase":"Phase 3","brief_title":"A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)","source_id_and_acronym":"NCT02411448 - RELAY","lead_sponsor":"Eli Lilly and Company","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • erlotinib • gefitinib • Cyramza (ramucirumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 545","initiation":"Initiation: 05/06/2015","start_date":" 05/06/2015","primary_txt":" Primary completion: 01/23/2019","primary_completion_date":" 01/23/2019","study_txt":" Completion: 12/16/2024","study_completion_date":" 12/16/2024","last_update_posted":"2024-03-18"},{"id":"0820c88c-d580-43f4-a9e2-5ba71774bd03","acronym":"","url":"https://clinicaltrials.gov/study/NCT05993234","created_at":"2023-08-15T19:10:22.621Z","updated_at":"2024-07-02T16:35:15.308Z","phase":"","brief_title":"A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)","source_id_and_acronym":"NCT05993234","lead_sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • Cyramza (ramucirumab) • irinotecan"],"overall_status":"Recruiting","enrollment":" Enrollment 257","initiation":"Initiation: 12/05/2023","start_date":" 12/05/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-03-11"}]